$KRYS · The Motley Fool · 2026-11-14
KRYS 是一家优秀、盈利且处于早期增长的生物科技公司:已上市的 Vyjuvek 盈利能力很强,第三季度营收 1.27 亿美元、同比增长 30%,毛利率 94%,累计营收超过 10 亿美元、现金 12 亿美元;公司正拓展至其他罕见病和国际市场,并批准了两年内 4 亿美元的股票回购。财报后股价下跌 10% 以上,反映两项临床数据读出推迟至 2027 年,说话者称这并不令人担忧;对生物科技投资者而言,该股至少应列入观察名单,甚至买入名单。
播放时,YouTube 可能接收设备与播放信息并使用 Cookie。 隐私说明 · Google 隐私政策
逐段跳播
接下来换一个完全不同的板块,我们应该聊聊医疗保健。我要讲的是 Crystal Biotech,股票代码是 KRYS。
Moving on to a completely different sector, we should talk about healthcare. I'm going to talk about Crystal Biotech, and the code is K R Y S.
那么,Crystal Biotech 如果你不熟悉的话,它在新兴生物科技公司中算是一个不太为人所知的名字。这是一家处于商业化阶段的公司。他们已经拥有一款经过验证且利润很高的产品。所以,这并不是押注未来某项临床试验的结果。
So, Crystal Biotech, if you're not familiar with it, is a bit of an unknown in the world of emerging biotech companies. This is a company in the commercial phase. They already have a proven and highly profitable product.
So, this is not a bet on the results of a future clinical trial.
Crystal Biotech 的旗舰产品是一款名为 Vyjuvek 的疗法。它是全球首个可以在家中局部外用的基因疗法。它治疗一种称为萎缩性表皮坏死松解症(DEB)的疾病。这是一种严重且极其疼痛的遗传性皮肤病。
由于胶原蛋白基因缺陷,它会导致可怕的溃疡和慢性伤口。
Crystal Biotech's flagship product is a treatment called Vyjuvek. It is the world's first gene therapy that can be applied topically at home. It treats a condition known as atrophic epidermal necrolysis or (DEB).
This is a severe and extremely painful hereditary skin disease. It causes horrific ulcers and chronic wounds due to a defect in collagen genes.
Crystal Biotech 的 Vigovic 药物使用一种经过改造的疱疹病毒,把该基因的有效副本直接递送到患者的皮肤细胞中。因此,它实际上是作为一种简单的凝胶来使用,患者可以在家中反复使用。这不是靠一次性的单次注射完成的。
Crystal Biotech's Vigovic drug uses a modified version of the herpes virus to deliver a working copy of that gene directly into the patient's skin cells. Therefore, it is actually applied as a simple gel that the patient can use repeatedly at home.
This is not done with a single, one-time injection, you know.
这种可重复给药的递送平台不仅对这一种罕见病有用。它是 Crystal Biotech 目前正在扩展的基础,以纳入针对肺部、眼部其他罕见疾病以及其他罕见皮肤疾病的新项目。
This re-dose delivery platform is not only useful for this one rare disease. It is the foundation that Crystal Biotech is now expanding to include new programs targeting other rare conditions in the lungs, eyes, and other rare skin disorders.
所以,他们围绕单纯疱疹病毒构建平台的方式真的很有意思。这种病毒经过长期进化,擅长两件事:感染皮肤细胞,以及在足够长的时间里躲避免疫系统,从而在人体内终身存在而不被永久清除。因此,Crystal Biotic 的平台实际上受益于这两种天然特性,但用于治疗目的。
这意味着他们能够替换患者所缺失的任何基因的纠正副本,同时保留病毒侵入皮肤细胞的天然能力,而不会在患者体内引发任何负面免疫反应。
So it's really interesting, you know, how they built their platform around the herpes simplex virus. This is a virus that has evolved over a long period to be good at two things: infecting skin cells and hiding from the body's immune system long enough to remain in a person for life without being permanently eliminated.
Thus, the Crystal Biotic platform actually benefits from these two natural properties, but for a therapeutic purpose. This means they are able to replace a corrective copy of any gene the patient is missing, while preserving the virus’s natural ability to infiltrate skin cells without triggering any kind of negative immune response in the patient.
现在,我们来看一些公司业绩的数字;他们最近在11月初公布了第三季度业绩。全球收入达到1.27亿美元。这同比增长了30%。自 Vigovic 上市以来,他们的累计收入现已略高于10亿美元。
他们的毛利率为94%。本季度结束时,他们拥有约12亿美元的现金和投资。
Now, let's put some numbers on the company's performance; they recently released their third-quarter results in early November. Global revenues reached $127 million. That was a 30% year-on-year increase.
Their cumulative revenue since the launch of Vigovic now stands at just over $1 billion. Their gross profit margin is 94%. They ended the quarter with approximately $1.2 billion in cash and investments.
现在,自他们公布财报以来,股价承受了一些压力。在财报发布当天,它实际上下跌了10%或更多。这主要是因为管理层透露,他们有两个产品线候选药物的少量关键临床数据读出被推迟到2027年,而不是在年底前公布。
Now, the stock has come under some pressure since they announced their earnings. It actually dropped by 10% or more on the day of their earnings report. This was primarily because the administration revealed that they had a small number of key clinical data readouts for two of their product line candidates that had been postponed to 2027 instead of being released before the end of the year.
因此,他们有一个针对眼部罕见疾病的候选疗法。他们将在明年初公布正在进行的临床试验的初步结果。他们有一款针对囊性纤维化的疗法,其结果现已推迟到2027年上半年。这并不表明工作上有什么值得担心的,但这是你应该了解的情况。
Therefore, they have a therapeutic candidate that targets a rare condition in the eye. They will report preliminary results from their ongoing clinical trials early next year. They have a treatment for cystic fibrosis whose results have now been postponed until the first half of 2027.
This does not indicate anything to worry about in terms of work, but it is just something you should be aware of.
如你所知,Crystal Biotechnology 继续其国际扩张。他们当然已经在美国扩展并推出了产品,并已在德国和意大利等市场完成了定价和支付谈判。因此,他们最早将在2027年初在其中一些市场推出产品。他们已经在受益于欧洲的早期上市以及日本的扩张。
As you know, Crystal Biotechnology continues its international expansion. They have, of course, expanded and launched their products within the United States, and have finalized pricing and payment negotiations in markets such as Germany and Italy.
So they will be launching their products in some of these markets as early as the beginning of 2027. They are already benefiting from early launches in Europe as well as expansion in Japan.
我还想指出,Crystal Biotechnology 的董事会已批准一项4亿美元的股票回购计划,将在未来两年内实施。
I would also like to point out that the board of directors of Crystal Biotechnology has approved a $400 million share buyback program that will be implemented over the next two years.
所以,这是一家很棒的公司,正处于增长的早期阶段。公司有一款主要的高利润产品,但正在迅速扩展到其他罕见疾病领域。这是一家盈利能力强、利润率高的公司,如果你有兴趣把钱投资于生物科技股票,它至少可能值得列入你的观察名单,甚至买入名单。
So, it's a great company and in its early stages of growth. The company has one major, highly profitable product, but is rapidly expanding into other areas of rare diseases. It is a profitable company with a high profit margin, and it may be one to put on your watchlist at least, if not your buy list, if you are interested in investing your money in biotechnology stocks.